TGFBI and neoplasm: The finding that the two main eBL risk factors compromise TGFBI gene expression through a molecular mechanism of DNA methylation-dependent gene silencing, recurrent in many cancers with a defined tumor suppressor function for TGFBI, suggests for the first time the same possible role in the context of lymphoma.